Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations

Blood

Volumn 107, Issue 7, 2006, Pages 2993-3001

  Zhang, Chunyan ^b   Todorov, Ivan ^b   Zhang, Zhifang ^b   Liu, Yinping ^b   Kandeel, Fouad ^b   Forman, Stephen ^b   Strober, Samuel ^b   Zeng, Defu ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL TRANSPLANTATION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; LUPUS VULGARIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; SCLERODERMA; SKIN DEFECT; SPLEEN CELL; T LYMPHOCYTE; THYMECTOMY; THYMOCYTE;

EID: 33645505721     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3623     Document Type: Article

References (62)

1. Sullivan KM. Graft-vs-host disease. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 2004:635-664.
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233.
3. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200-4206.
4. Farag SS. Chronic graft-versus-host disease: where do we go from here? Bone Marrow Transplant. 2004;33:569-577.
5. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: a study of 53 long-term-surviving patients. Transplantation. 1988;46:238-240.
6. Lister J, Messner H, Keystone E, Miller R, Fritzler MJ. Autoantibody analysis of patients with graft versus host disease. J Clin Lab Immunol. 1987;24:19-23.
7. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505-511.
8. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603-2606.
9. Ferrara J, Antin, J. The pathophysiology of graft-vs-host disease. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 2004:353-368.
10. van der Veen FM, Rolink AG, Gleichmann E. Autoimmune disease strongly resembling systemic lupus erythematosus (SLE) in F1 mice undergoing graft-versus-host reaction (GVHR). Adv Exp Med Biol. 1982;149:669-677.
11. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Autoantibodies in chronic graft versus host result from cognate T-B interactions. J Exp Med. 1990;171:503-517.
12. Via CS, Shearer GM. T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol Today. 1988;9:207-213.
13. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Allotype-specific immunoregulation of autoantibody production by host B cells in chronic graft-versus host disease. J Immunol. 1990;144:916-922.
14. Sekiguchi DR, Jainandunsing SM, Fields ML, et al. Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in antidouble-stranded DNA B cells. J Immunol. 2002;168:4142-4153.
15. Sekiguchi DR, Eisenberg RA, Weigert M. Secondary heavy chain rearrangement: a mechanism for generating anti-double-stranded DNA B cells. J Exp Med. 2003;197:27-39.
16. Parkman R. Clonal analysis of murine graft-vs-host disease, I: phenotypic and functional analysis of T lymphocyte clones. J Immunol. 1986;136:3543-3548.
17. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma, I: description of model systems. Cell Immunol. 1983;77:1-12.
18. Claman HN, Jaffee BD, Huff JC, Clark RA. Chronic graft-versus-host disease as a model for scleroderma, II: mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 1985;94:73-84.
19. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088-3098.
20. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 1987;139:2511-2515.
21. Liang Y, Huang T, Zhang C, et al. Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood. 2005;105:2180-2188.
22. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest. 2003;112:1211-1222.
23. Zeng D, Lewis D, Dejbakhsh-Jones S, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med. 1999;189:1073-1081.
24. Zeng D, Dick M, Cheng L, et al. Subsets of transgenic T cells that recognize CD1 induce or prevent murine lupus: role of cytokines. J Exp Med. 1998;187:525-536.
25. Zeng D, Lee MK, Tung J, Brendolan A, Strober S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol. 2000;164:5000-5004.
26. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol. 1987;139:1840-1849.
27. Pierres M, Rebouah JP, Liabeuf A, Dosseto M. Mouse monoclonal antibody against Lyt-1.1 alloantigen. J Immunogenet. 1981;8:67-71.
28. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104:1565-1573.
29. Chen F, Maldonado MA, Madaio M, Eisenberg RA. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J Immunol. 1998;161:5880-5885.
30. Choudhury A, Maldonado MA, Cohen PL, Eisenberg RA. The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol. 2005;174:7600-7609.
31. Parkman R. Chronic graft-versus-host disease. Curr Opin Hematol. 1998;5:22-25.
32. Tsoi MS, Storb R, Jones E, et al. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol. 1978;120:1485-1492.
33. Hahn BH. Antibodies to DNA. N Engl J Med. 1998;338:1359-1368.
34. Kotzin BL. Systemic lupus erythematosus. Cell. 1996;85:303-306.
35. Huang CM, Parsons M, Oi VT, Huang HJ, Herzenberg LA. Genetic characterization of mouse immunoglobulin allotypic determinants (allotopes) defined by monoclonal antibodies. Immunogenetics. 1983;18:311-321.
36. Anderson RE, Olson GB, Autry JR, Howarth JL, Troup GM, Bartels PH. Radiosensitivity of T and B lymphocytes, IV: effect of whole body irradiation upon various lymphoid tissues and numbers of recirculating lymphocytes. J Immunol. 1977;118:1191-1200.
37. Durum SK, Gengozian N. The comparative radiosensitivity of T and B lymphocytes. Int J Radiat Biol Relat Stud Phys Chem Med. 1978;34:1-15.
38. Pazdernik TL, Nishimura T. Radiosensitivity of different B and T subpopulations of lymphocytes in the mouse spleen. Agents Actions. 1978;8:229-237.
39. Fukushi N, Arase H, Wang B, et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci U S A. 1990;87:6301-6305.
40. Desbarats J, Lapp WS. Thymic selection and thymic major histocompatibility complex class II expression are abnormal in mice undergoing graft-versus-host reactions. J Exp Med. 1993;178:805-814.
41. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401-406.
42. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-399.
43. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
44. Zeng D, Lan F, Hoffmann P, Strober S. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation. 2004;77:S9-S11.
45. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med. 1987;166:798-803.
46. Datta SK, Patel H, Berry D. Induction of a cationic shift in IgG anti-DNA autoantibodies: role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. J Exp Med. 1987;165:1252-1268.
47. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001;28:121-129.
48. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft versus host disease. Blood. 2005;105:4885-4891.
49. Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol. 1994;152:1609-1617.
50. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104:2187-2193.
51. Hakim FT, Payne S, Shearer GM. Recovery of T cell populations after acute graft-vs-host reaction. J Immunol. 1994;152:58-64.
52. Klein L, Klugmann M, Nave KA, Tuohy VK, Kyewski B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med. 2000;6:56-61.
53. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 1995;16:289-295.
54. Bendelac A, Bonneville M, Kearney JF. Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol. 2001;1:177-186.
55. Melchers F, Rolink, A. B-lymphocyte development and biology. In: Paul W, ed. Fundamental Immunology. Philadelphia, PA: Lippincott-Raven; 1998:367-409.
56. Lin RH, Mamula MJ, Hardin JA, Janeway CA Jr. Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med. 1991;173:1433-1439.
57. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991;173:487-489.
58. Singh RR, Hahn BH. Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Immunol Rev. 1998;164:201-208.
59. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189:1639-1648.
60. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147-153.
61. La Cava A, Ebling FM, Hahn BH. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol. 2004;173:3542-3548.
62. Zheng SG, Wang JH, Koss MN, Quismorio F Jr, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol. 2004;172:1531-1539.